ReviewHuman vaccines & immunotherapeutics2026
Engineered bacterial therapeutics from synthetic biology to clinical translation: A multi-database scientometric analysis, 2000-2026.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engineered bacterial therapeutics integrate programmable strain engineering with biomedical functions such as sensing, delivery, immune modulation, microbiome intervention, and disease management. This study conducted a multi-database bibliometric analysis to map the knowledge structure, collaboration patterns, and translational direction of this field. Bibliographic records were retrieved from Web of Science Core Collection, Scopus, and PubMed for publications from 1 January 2000 to 1 June 2026. After document-type filtering, time restriction, deduplication, language screening, and manual eligibility assessment, 1,730 English-language articles and reviews were included. CiteSpace 6.4.R1, VOSviewer 1.6.20, and the bibliometrix R package were used to analyze publication trends, collaboration networks, journal co-citation, dual-map citation trajectories, citation bursts, keyword co-occurrence, and thematic evolution. Publication output increased steadily, with faster growth after 2020; 2025 was the highest-output complete year, while 2026 represented a partial retrieval year. China and the United States were the leading contributors, although institutional collaboration remained regionally clustered. Co-citation, citation-burst, and keyword analyses showed a shift from bacterial chassis construction and circuit design toward engineered probiotics, gut microbiota-related therapy, cancer immunotherapy, drug delivery, live biotherapeutic products, and clinical translation. Persistent translational priorities include controllability, safety, manufacturing consistency, and regulatory alignment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.